[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE472609T1 - Kombinatorische bibliotheken von monomerdomänen - Google Patents

Kombinatorische bibliotheken von monomerdomänen

Info

Publication number
ATE472609T1
ATE472609T1 AT02725828T AT02725828T ATE472609T1 AT E472609 T1 ATE472609 T1 AT E472609T1 AT 02725828 T AT02725828 T AT 02725828T AT 02725828 T AT02725828 T AT 02725828T AT E472609 T1 ATE472609 T1 AT E472609T1
Authority
AT
Austria
Prior art keywords
domains
multimers
immuno
monomer
methods
Prior art date
Application number
AT02725828T
Other languages
English (en)
Inventor
Joost Kolkman
Willem Stemmer
Original Assignee
Amgen Mountain View Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Mountain View Inc filed Critical Amgen Mountain View Inc
Application granted granted Critical
Publication of ATE472609T1 publication Critical patent/ATE472609T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068—Means for controlling the apparatus of the process
    • B01J2219/00702—Processes involving means for analysing and characterising the products
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymerisation Methods In General (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT02725828T 2001-04-26 2002-04-26 Kombinatorische bibliotheken von monomerdomänen ATE472609T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28682301P 2001-04-26 2001-04-26
US33720901P 2001-11-19 2001-11-19
US33335901P 2001-11-26 2001-11-26
US37410702P 2002-04-18 2002-04-18
PCT/US2002/013257 WO2002088171A2 (en) 2001-04-26 2002-04-26 Combinatorial libraries of monomer domains

Publications (1)

Publication Number Publication Date
ATE472609T1 true ATE472609T1 (de) 2010-07-15

Family

ID=27501442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02725828T ATE472609T1 (de) 2001-04-26 2002-04-26 Kombinatorische bibliotheken von monomerdomänen

Country Status (11)

Country Link
US (2) US20030082630A1 (de)
EP (1) EP1390535B1 (de)
JP (1) JP4369662B2 (de)
AT (1) ATE472609T1 (de)
AU (1) AU2002256371B2 (de)
CA (1) CA2444854A1 (de)
CY (1) CY1110808T1 (de)
DE (1) DE60236861D1 (de)
DK (1) DK1390535T3 (de)
PT (1) PT1390535E (de)
WO (1) WO2002088171A2 (de)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175756A1 (en) * 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050048512A1 (en) * 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US7999083B2 (en) 2002-12-13 2011-08-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7563600B2 (en) 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2432972A1 (en) * 2003-07-04 2005-01-04 Jeak L. Ding Sushi peptides, processes for making and uses thereof
CN101018559A (zh) * 2004-06-17 2007-08-15 安姆根山景公司 c－MET激酶结合蛋白
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060234299A1 (en) * 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
JP2008520208A (ja) * 2004-11-16 2008-06-19 アヴィディア リサーチ インスティテュート タンパク質骨格およびその使用
SG171481A1 (en) * 2005-01-03 2011-06-29 Hoffmann La Roche Hemopexin-like structure as polypeptide-scaffold
ATE414718T1 (de) * 2005-01-05 2008-12-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
AU2011253661B2 (en) * 2005-04-26 2013-06-13 Boehringer Ingelheim Rcv Gmbh & Co Kg Production of recombinant proteins by autoproteolytic cleavage of a fusion protein
DE602006013111D1 (de) * 2005-04-26 2010-05-06 Boehringer Ingelheim Rcv Gmbh Affinitätsliganden
JP2007008926A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
US20060286047A1 (en) * 2005-06-21 2006-12-21 Lowe David J Methods for determining the sequence of a peptide motif having affinity for a substrate
US7820790B2 (en) 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
WO2007009018A2 (en) * 2005-07-13 2007-01-18 Amgen Mountain View Inc. Il-6 binding proteins
CN103432568A (zh) 2005-11-23 2013-12-11 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
GB2433591A (en) * 2005-12-20 2007-06-27 Sharp Kk Method for functionalising a hydrophobic substrate
GB2433506A (en) * 2005-12-20 2007-06-27 Sharp Kk A method of producing a multimeric capture agent
GB2433505A (en) * 2005-12-20 2007-06-27 Sharp Kk Capture agents for binding a ligand
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
EP1844788B1 (de) * 2006-04-13 2010-07-14 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. HER-2/neu Multipeptidimpfstoff
US20090087840A1 (en) * 2006-05-19 2009-04-02 Codon Devices, Inc. Combined extension and ligation for nucleic acid assembly
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
US20100292090A1 (en) 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2008027558A2 (en) 2006-08-31 2008-03-06 Codon Devices, Inc. Iterative nucleic acid assembly using activation of vector-encoded traits
AU2007292890A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
PT2486941T (pt) 2006-10-02 2017-05-30 Squibb & Sons Llc Anticorpos humanos que ligam a cxcr4 e utilizações dos mesmos
JP2010507099A (ja) 2006-10-16 2010-03-04 ザ アリゾナ ボード オブ リージェンツ ア ボディ コーポレイト オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティー 合成抗体
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
CA2671457C (en) 2006-12-01 2017-09-26 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
WO2008076368A2 (en) * 2006-12-13 2008-06-26 Codon Devices, Inc. Fragment-rearranged nucleic acids and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP3320911B1 (de) 2006-12-18 2021-12-01 Acceleron Pharma Inc. Aktivin-actrii-antagonisten und ihre verwendungen zur erhöhung der erythrozytenspiegel
EP2111229B1 (de) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Zusammensetzungen enthaltend Activin-ActRIIA-Antagonisten zur Verwendung bei der Vorbeugung oder Behandlung der Brustkrebs-Metastasen oder des Brustkrebs Knochenverlustes
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
NZ579010A (en) 2007-02-20 2012-03-30 Anaptysbio Inc Somatic hypermutation systems
AU2008226067B2 (en) 2007-03-12 2012-11-08 Esbatech, An Alcon Biomedical Research Unit Llc Sequence based engineering and optimization of single chain antibodies
EA200901646A1 (ru) 2007-06-05 2010-08-30 Йел Юниверсити Ингибиторы рецепторных тирозинкиназ и их применение
BRPI0813287A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Planejamento e otimização baseados na sequência de anticorpos de cadeia única
PL2158315T3 (pl) 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
US8921279B2 (en) 2007-06-26 2014-12-30 F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H Display of binding agents
CA2697517A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Cancer-related genes, cdca5, epha7, stk31 and wdhd1
WO2009028521A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis
BRPI0815769A2 (pt) 2007-08-24 2017-08-08 Oncotherapy Science Inc Ebi3, dlx5, nptx1 e cdkn3 como genes alvo da terapia e diagnóstico de câncer de pulmão
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2964398C (en) 2007-09-14 2023-03-07 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
LT3241843T (lt) 2008-06-25 2021-09-27 Novartis Ag Imuninių rišiklių tirpumo optimizavimas
CA2729100C (en) 2008-06-26 2018-01-02 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
DK2318028T3 (da) 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
ES2752025T3 (es) 2008-07-25 2020-04-02 Wagner Richard W Métodos de cribado de proteínas
KR101127476B1 (ko) * 2008-08-11 2012-03-23 아주대학교산학협력단 크링글 도메인의 구조에 기반한 단백질 골격 라이브러리 및 그 용도
US9089610B2 (en) 2008-08-19 2015-07-28 Nektar Therapeutics Complexes of small-interfering nucleic acids
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
WO2010054264A1 (en) * 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
AU2010207552A1 (en) 2009-01-21 2011-09-01 Oxford Biotherapeutics Ltd. PTA089 protein
SG173742A1 (en) 2009-03-05 2011-09-29 Medarex Inc Fully human antibodies specific to cadm1
ES2575695T3 (es) 2009-03-30 2016-06-30 Acceleron Pharma Inc. Antagonistas de BMP-ALK3 y sus usos para estimular el crecimiento óseo
MA33276B1 (fr) 2009-04-20 2012-05-02 Oxford Biotherapeutics Ltd Anticorps spécifiques à la cadhérine-17
EP2722055A1 (de) 2009-08-17 2014-04-23 Tracon Pharmaceuticals, Inc. Kombination Therapy mit AntiKörpern und therapeutika gegen VEGF für die Behandlung von Krebs
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
AU2010292203A1 (en) 2009-09-09 2012-04-12 Acceleron Pharma Inc. ActRIIb antagonists and dosing and uses thereof
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
EP2496605A1 (de) 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 als therapeutisches und diagnostisches ziel
WO2011056872A2 (en) 2009-11-03 2011-05-12 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
CN102640001A (zh) 2009-11-05 2012-08-15 诺瓦提斯公司 预测纤维化进展的生物标记物
US9216414B2 (en) 2009-11-25 2015-12-22 Gen9, Inc. Microfluidic devices and methods for gene synthesis
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
WO2011085075A2 (en) 2010-01-07 2011-07-14 Gen9, Inc. Assembly of high fidelity polynucleotides
BR112012019902A2 (pt) 2010-02-10 2019-09-24 Novartis Ag "método e compostos para o crescimento muscular"
EP2563380B1 (de) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten der cysteinyl-trna-synthetase
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
CA2797271C (en) 2010-04-28 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
JP5991963B2 (ja) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2566515B1 (de) 2010-05-03 2017-08-02 aTyr Pharma, Inc. Innovative entdeckung von therapeutischen und diagnostischen mitteln sowie antikörperzusammensetzungen im zusammenhang mit proteinfragmenten von arginyl-trna-synthetasen
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
ES2623805T3 (es) 2010-05-03 2017-07-12 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2011140267A2 (en) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
US9238042B2 (en) 2010-05-13 2016-01-19 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
EP2568996B1 (de) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutische, diagnostische und antikörperhaltige zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP3560962A1 (de) 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc. Verarbeitbare einkettige moleküle und daraus hergestellte polypeptide
EP2593125B1 (de) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von glycyl-trna-synthetasen
CA3132011A1 (en) 2010-11-12 2012-06-14 Gen9, Inc. Methods and devices for nucleic acids synthesis
EP2637780B1 (de) 2010-11-12 2022-02-09 Gen9, Inc. Proteinanordnungen und verfahren zu ihrer herstellung und verwendung
RU2013145556A (ru) 2011-03-11 2015-04-20 Селджин Корпорейшн Применение 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2,6-диона в лечении иммунных и воспалительных заболеваний
TWI540127B (zh) 2011-03-11 2016-07-01 西建公司 ３－（５－胺基－２－甲基－４－氧基－４ｈ－喹唑啉－３－基）－六氫吡啶－２，６－二酮之固體型式及其醫藥組合物及用途
ES2828482T3 (es) 2011-06-13 2021-05-26 Csl Ltd Anticuerpos contra el g-csfr y su uso
GEP201706667B (en) 2011-06-28 2017-05-25 Berlin - Chemie Ag Antibodies to adp-ribosyl cyclase 2
JP6113721B2 (ja) 2011-06-28 2017-04-12 オックスフォード ビオトヘラペウトイクス エルティーディー． 治療標的及び診断標的
CN104066844B (zh) 2011-08-26 2016-12-07 Gen9股份有限公司 用于核酸的高保真组装的组合物和方法
EP2771351B1 (de) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1-epitope und verfahren zu ihrer verwendung
WO2013074840A1 (en) 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
AU2013207927B2 (en) 2012-01-10 2017-11-02 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
IN2014MN01642A (de) 2012-02-16 2015-07-03 Atyr Pharma Inc
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
US10081807B2 (en) 2012-04-24 2018-09-25 Gen9, Inc. Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2014004393A1 (en) 2012-06-25 2014-01-03 Gen9, Inc. Methods for nucleic acid assembly and high throughput sequencing
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
SG11201500998QA (en) 2012-08-09 2015-04-29 Celgene Corp Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
UA114521C2 (uk) 2012-08-09 2017-06-26 Селджин Корпорейшн Солі і тверді форми (s)-3-(4-((4-морфолінометил)-бензил)оксі)-1-оксоізоіндолін-2-іл)-піперидин-2,6-діону і композиції, які їх включають, і способи їхнього застосування
CA3092279C (en) 2012-08-09 2023-08-08 Celgene Corporation Treatment of immune-related and inflammatory diseases
WO2014023315A1 (en) 2012-08-10 2014-02-13 Aarhus Universitet Multimerization through beta-strand swapping in ccp domains
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2014055784A1 (en) 2012-10-03 2014-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
EP3608419A1 (de) 2012-10-24 2020-02-12 Celgene Corporation Biomarker zur verwendung bei der behandlung von anämie
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
WO2014074905A1 (en) 2012-11-08 2014-05-15 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
KR102536723B1 (ko) 2012-12-13 2023-05-30 이뮤노메딕스, 인코오포레이티드 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2961412A4 (de) 2013-02-26 2016-11-09 Triact Therapeutics Inc Krebstherapie
CA3175634A1 (en) 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
EP2774930A1 (de) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocenverbindungen und markierte Moleküle damit für In-vivo-Bildgebung
US9157910B2 (en) 2013-03-15 2015-10-13 Abbott Laboratories Assay with increased dynamic range
DK2968503T3 (en) 2013-03-15 2018-12-03 Intrinsic Lifesciences Llc ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
US9005901B2 (en) 2013-03-15 2015-04-14 Abbott Laboratories Assay with internal calibration
WO2015015401A2 (en) 2013-08-02 2015-02-05 Pfizer Inc. Anti-cxcr4 antibodies and antibody-drug conjugates
EP3044593A4 (de) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Krebstherapie
TR201900665T4 (tr) 2013-11-28 2019-02-21 B Creative Sweden Ab Diyabetik nefropatinin tedavi yöntemi.
US10543270B2 (en) 2013-12-18 2020-01-28 Csl Limited Methods of treating wounds in a diabetic subject
EP3572424B1 (de) 2014-03-20 2022-04-20 Bristol-Myers Squibb Company Serumalbuminbindende fibronectin-typ-iii-domänen
JP6789124B2 (ja) 2014-07-03 2020-11-25 イエール ユニバーシティ 腫瘍形成を抑制するディコップ２（Ｄｉｃｋｋｏｐｆ２）（Ｄｋｋ２）阻害
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US20170304460A1 (en) 2014-10-01 2017-10-26 Medimmune, Llc Method of conjugating a polypeptide
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
HUE046181T2 (hu) 2014-11-07 2020-02-28 Sesen Bio Inc Javított ellenanyagok IL-6 ellen
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3227675B1 (de) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii-antagonisten und verwendungen davon zur behandlung von myelodysplastischem syndrom
EP3298034A4 (de) 2015-05-20 2019-02-13 Celgene Corporation In-vitro-zellkulturverfahren zur beta-thalassämie mittels fallen von activin-typ-ii-rezeptor-liganden
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
JP6893504B2 (ja) 2015-09-23 2021-06-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 速い解離速度を有する血清アルブミン結合フィブロネクチンタイプｉｉｉドメイン
RU2018119317A (ru) 2015-10-28 2019-12-04 Йейл Юниверсити Гуманизированное антитело к dkk2 и его применение
EP3383398A1 (de) 2015-12-02 2018-10-10 Celgene Corporation Zyklustherapie unter verwendung von 3-(5-amino-2-methyl-4-oxo-4h-chinazolin-3-yl)-piperidin-2,6-dion
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
CN110023339A (zh) 2016-09-23 2019-07-16 Csl有限公司 凝血因子结合蛋白及其应用
US20180258064A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
EP3697812A4 (de) 2017-10-18 2021-09-22 CSL Limited Menschliche serumalbuminvarianten und ihre verwendungen
DK3717011T5 (da) 2017-11-29 2024-08-26 Csl Ltd Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
WO2020176553A1 (en) * 2019-02-25 2020-09-03 Sense Therapeutics Inc. Intracellular mutation targeting therapy
WO2020183133A1 (en) 2019-03-08 2020-09-17 Oxford Genetics Limited Method of selecting for antibodies
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
IL294045A (en) 2019-12-20 2022-08-01 Hudson Inst Med Res Proteins that bind to cxcl10 and their uses
KR20240067079A (ko) 2021-08-30 2024-05-16 라센 테라퓨틱스 1, 인코포레이티드 항-IL-11Rα 항체
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2024088921A1 (en) 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists
WO2024148240A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
WO2024148241A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088994B1 (de) * 1982-03-15 1991-06-19 Schering Corporation Hybride DNS, damit hergestellte Bindungszusammensetzung und Verfahren dafür
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0787185A2 (de) * 1994-10-20 1997-08-06 MorphoSys AG Gezielte heterozusammensetzung von rekombinanten proteinen bei multifunktionalen komplexen
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP2002501721A (ja) * 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
US6030771A (en) * 1997-08-25 2000-02-29 Centers For Disease Control And Prevention Mosaic protein and restriction endonuclease assisted ligation method for making the same
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU765218B2 (en) * 1999-03-16 2003-09-11 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The A novel chimeric protein for prevention and treatment of HIV infection
AUPQ339899A0 (en) * 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof

Also Published As

Publication number Publication date
WO2002088171A2 (en) 2002-11-07
EP1390535A4 (de) 2005-01-05
DE60236861D1 (de) 2010-08-12
CA2444854A1 (en) 2002-11-07
EP1390535A2 (de) 2004-02-25
CY1110808T1 (el) 2012-05-23
EP1390535B1 (de) 2010-06-30
JP4369662B2 (ja) 2009-11-25
US20030082630A1 (en) 2003-05-01
DK1390535T3 (da) 2010-12-06
JP2005519579A (ja) 2005-07-07
US20050221384A1 (en) 2005-10-06
PT1390535E (pt) 2010-10-04
AU2002256371B2 (en) 2008-01-10
WO2002088171A3 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
ATE472609T1 (de) Kombinatorische bibliotheken von monomerdomänen
WO2004044011A3 (en) Combinatorial libraries of monomer domains
DK0873340T3 (da) Heterocyklisk substituerede cyclopentanforbindelser
WO2020051562A3 (en) Compositions and methods for improving base editing
CO5690651A2 (es) Composicion y metodos para recubrir latas para alimentos
DE69714020D1 (de) Rückgewinnung von taxanen aus koniferen
DK0693073T3 (da) Bicykliske ansamyciner og deres anvendelse som antitumormidler
CY1108344T1 (el) Φορεις εκφρασης που περιεχουν τον mcmv ie2 υποκινητη
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
EA200601124A1 (ru) Противовирусные фармацевтические композиции
DE69634127D1 (de) Zellfreie synthese von polyketiden
TR200101858T2 (tr) JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
CY1114626T1 (el) Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους
ATE466855T1 (de) Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
CY1105758T1 (el) Τροποποιημενη απιμιναση αργινινης
DE60131021D1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
DE50115349D1 (de) Verfahren zur selektion von partikeln
EA200500064A1 (ru) Многофункциональные маркеры продуктов и способы их получения и применения
WO2002068698A3 (en) Use of nucleic acid libraries to create toxicological profiles
ATE553185T1 (de) Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle
WO2004101764A3 (en) Methods of modulating metastasis and skeletal related events resulting from metastases
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
DE60312895D1 (de) Emulsionen mit oberflächenmodifizierten organischen molekülen
ATE447628T1 (de) Einzelsequenzhybridisierungssonden
CY1105675T1 (el) Πρωτεϊνη ροσδενουσα αγγειοστατινη

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390535

Country of ref document: EP